568,647 Shares in ProKidney Corp. (NASDAQ:PROK) Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. bought a new stake in ProKidney Corp. (NASDAQ:PROK - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 568,647 shares of the company's stock, valued at approximately $961,000. Hennion & Walsh Asset Management Inc. owned about 0.19% of ProKidney at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Suvretta Capital Management LLC raised its position in ProKidney by 32.1% in the third quarter. Suvretta Capital Management LLC now owns 12,341,266 shares of the company's stock valued at $23,695,000 after purchasing an additional 3,000,000 shares during the period. Geode Capital Management LLC raised its holdings in shares of ProKidney by 102.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,203,934 shares of the company's stock valued at $4,232,000 after buying an additional 1,112,933 shares during the period. State Street Corp lifted its position in ProKidney by 16.2% during the 3rd quarter. State Street Corp now owns 1,428,318 shares of the company's stock worth $2,742,000 after acquiring an additional 198,836 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in ProKidney by 150.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 749,718 shares of the company's stock worth $1,439,000 after acquiring an additional 450,548 shares during the period. Finally, Bank of New York Mellon Corp grew its position in ProKidney by 44.6% in the second quarter. Bank of New York Mellon Corp now owns 179,236 shares of the company's stock valued at $441,000 after acquiring an additional 55,266 shares in the last quarter. Hedge funds and other institutional investors own 51.59% of the company's stock.

ProKidney Trading Up 0.6 %

NASDAQ PROK traded up $0.01 during mid-day trading on Monday, reaching $1.66. 295,119 shares of the company's stock traded hands, compared to its average volume of 477,501. ProKidney Corp. has a 1-year low of $1.18 and a 1-year high of $4.44. The company has a fifty day simple moving average of $1.80 and a 200-day simple moving average of $2.00. The company has a market cap of $484.16 million, a price-to-earnings ratio of -3.02 and a beta of 1.32.

ProKidney (NASDAQ:PROK - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.14). Equities research analysts forecast that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. initiated coverage on shares of ProKidney in a research note on Monday, September 30th. They issued a "neutral" rating for the company. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $4.50.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.